Bharat Biotech to supply COVAXIN to Brazil
Bharat Biotech to supply COVAXIN to Brazil
14 January 2021 | News In principle, it is understood between both parties that supplies of COVAXIN™ to be prioritised for the public market, through a direct procurement by the Govt of Brazil
Source: bharatbiotech.com
Bharat Biotech announced that it has signed an agreement with Precisa Medicamentos for the supplies of COVAXIN™ to Brazil.
A team from Precisa Medicamentos has visited the Bharat Biotech facility last week to discuss potential export possibilities of COVAXIN™, India’s first indigenous vaccine for COVID-19. The team met Dr Krishna Ella, Chairman and Managing Director, Bharat Biotech on the January 7-8 at the Bharat Biotech facility in Genome Valley, Hyderabad. During the discussion, André Aranha Corrêa do Lago, Ambassador of Brazil to India, joined on a virtual platform. He expressed his keen interest on behalf of the Govt of Brazil, towards the procurement of
Bharat Biotech inks deal with Precisa Medicamentos for supply of COVAXIN to Brazil
Bharat Biotech has informed that the supplies of Covaxin will be prioritised for the public market, through a direct procurement by the Government of Brazil.
Bharat Biotech s Covaxin was granted restricted emegency use approval in clinical trial mode on January 2.
Hyderabad-based Bharat Biotech announced on January 12 that it has signed an agreement with Precisa Medicamentos to supply its coronavirus vaccine Covaxin to Brazil.
The vaccine maker said a team from Precisa Medicamentos had visited its facility last week to discuss potential export possibilities of Covaxin. They had met Dr Krishna Ella on January 7 and 8 and were joined by Ambassador of Brazil to India André Aranha Corrêa do Lago, who “expressed his keen interest on behalf of the Government of Brazil to procure Covaxin”.
Bharat Biotech to supply Covaxin to Brazil, inks deal with Precisa Medicamentos
The Government of Brazil will procure Covaxin directly from Bharat Biotech while supply to the private market will be subjected to authorisation from Brazilian regulatory authority ANVISA.
advertisement
UPDATED: January 12, 2021 18:27 IST
64 envoys from various countries visiting Bharat Biotech s facility in Hyderabad on December 9 (Photo Credits: PTI)
Bharat Biotech Tuesday signed an agreement with Precisa Medicamentos to supply its Covid-19 vaccine Covaxin to Brazil. Earlier, a team from Precisa Medicamentos visited the Bharat Biotech facility ahead of discussing potential export possibilities of India s first indigenous vaccine for cororonavirus.
According to a press release by the Hyderabad-based pharma company, the team met Bharat Biotech chief Dr Krishna Ella on January 7 and January 8 at its facility in Hyderabad s Genome Valley. Ambassador of Brazil to India, André Aranha Corrêa do Lago al
Bharat Biotech inks pact with Precisa Med to supply Covaxin to Brazil
Premium
The supplies of Covaxin will be prioritized for public market, through direct procurement by Brazil government
The supplies of Covaxin to private market would be based upon receipt of market authorization from Brazilian regulatory authority ANVISA
Share Via
Read Full Story
Bharat Biotech on Tuesday announced that it has signed an agreement with Precisa Medicamentos for the supply of its indigenously manufactured Covid-19 vaccine Covaxin to Brazil.
The supplies of Covaxin will be prioritized for public market, through direct procurement by Brazil government, the company said in a statement.
A volunteer being vaccinated by a medic during the Bharat Biotech s Covaxin human trial. (PTI)
HYDERABAD: Vaccine maker Bharat Biotech on Tuesday said it has inked an agreement with Brazil’s Precisa Medicamentos for distribution of India’s first indigenous Covid-19 vaccine Covaxin in the Brazilian market. The Covaxin doses will be manufactured in India and exported to Brazil where they will be distributed by Precisa.
According to Bharat Biotech, the two players have, agreed in principle, that the supplies of Covaxin will be prioritised for the public market through a direct procurement by the Brazilian government. The supplies to the private market will be made based on the market authorization from the Brazilian regulatory authority ANVISA.